SBBP

Q3'20

Last Updated:

Strongbridge Biopharma

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. We are called Strongbridge for a reason. Our name reflects the collective strength of our rare disease expertise, our product portfolio and pipeline, and our patient-driven culture—one that is fueled by performance, precision and heart. Together, we are working to remove the barriers and isolation associated with rare neuromuscular and endocrine diseases in order to connect patients with the life-enhancing treatment options they deserve. Strongbridge is incorporated in Ireland, and its U.S. headquarters are located just outside of Philadelphia, PA. Strongbridge Biopharma is publicly traded on the NASDAQ Global Market under the ticker symbol SBBP.

Rare Focus. Rare Commitment. Rare Passion. That’s Strongbridge.

Cash

$81.8M

Burn Rate (Quarterly)

-$3.2M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

KEVEYIS® (dichlorphenamide)

Primary Periodic Paralysis

Quarterly Sales (Approved)

February 26, 2021 (Est)

RECORLEV (levoketoconazole)

Endogenous Cushing's syndrome

NDA Submission

Q1 2021

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon